Profile data is unavailable for this security.
About the company
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.
- Revenue in AUD (TTM)583.48k
- Net income in AUD-17.08m
- Incorporated1975
- Employees0.00
- LocationDimerix Ltd425 Smith Street, FitzroyMELBOURNE 3065AustraliaAUS
- Phone+61 30081-3321
- Fax+61 89388-8256
- Websitehttps://dimerix.com/
